spacer
home > white papers > Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific. - Novo Nordisk Pharmatech A/S
WHITE PAPERS
logo_Novo_NordiB.JPG

Novo Nordisk Pharmatech A/S

phone +45 5667 1000
email nnprinfo@novonordiskpharmatech.com
web http://www.novonordiskpharmatech.com
email Koebenhavnsvej 216, 4600 Koege

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.

Koege, Denmark, January 16th, 2019 – DKSH’s Business Unit Performance Materials, a leading ingredients and specialty chemicals distributor, will distribute Novo Nordisk Pharmatech’s pharmaceutical grade compounds (quats) to its large customer base in Australia, New Zealand, Vietnam, Japan, Indonesia, South Korea, Thailand, Malaysia, Philippines, China, Taiwan and Singapore.

Novo Nordisk Pharmatech manufactures its pharmaceutical quats in accordance with the cGMP Guide ICH Q7 for Active Pharmaceutical Ingredients (APIs), the highest available quality standard in the industry. The quats, Benzalkonium Chloride (BKC), Cetrimonium Bromide (CTAB), Cetrimide and Strong Cetrimide, act either as preservatives or active ingredients in a diverse range of applications, including ophthalmic, nasal, oral, dental or topical treatments and medical devices, such as wound care.

DKSH was chosen for its proven experience in providing Market Expansion Services along the entire value chain and its solid logistics infrastructure. As a regional expert with more than 150 years of experience in the Asian markets, DKSH offers an omni-channel approach that presents a one-stop regional solution for its clients. DKSH provides tailored valued-added services and a deep capillary distribution network that will enable the distribution of Novo Nordisk’s products in the twelve markets across Asia Pacific.

Tanja Schaffer, Vice President, Global Pharmaceutical Industry, DKSH, commented: “We are very pleased to partner with Novo Nordisk Pharmatech in Asia Pacific. Their pharmaceutical grade quats are a perfect fit for our API portfolio. We look forward to providing the quats to our large customer base in the region and to building a prosperous relationship with Novo Nordisk Pharmatech.”

Steve Profit, Global Sales & Marketing Director at Novo Nordisk Pharmatech A/S, added: “For Novo Nordisk Pharmatech it is critical that we have a distribution partner that shares our business ethics and drive to offer the best services to our customers, so we are delighted to have DKSH as our new distribution partner. Novo Nordisk Pharmatech’s FeF® GMP quats products fit perfectly with DKSH’s wide range of excipients, enabling the customers to take advantage of these synergies. Together, we will be able to offer the best quality and local distribution in the market. This will allow our customers to grow in this progressing global market.”

About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. Novo Nordisk Pharmatech A/S is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (quats) for the pharmaceutical, biopharmaceutical industry.

About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 825 business locations in 37 markets – 800 of them in Asia – and 31,970 specialized staff, DKSH generated net sales of CHF 11.0 billion in 2017. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.

DKSH Business Unit Performance Materials is a leading specialty chemicals distributor and provider of Market Expansion Services for performance materials, covering Europe, North America and the whole of Asia. The Business Unit sources, develops, markets and distributes a wide range of specialty chemicals and ingredients for pharmaceutical, personal care, food & beverage as well as various industrial applications. In addition, it creates innovative and cutting-edge concepts and applications in 29 innovation centers located worldwide. With 100 business locations in 31 markets and around 1,010 specialized staff, Business Unit Performance Materials generated net sales of CHF 894.1 million in 2017.

For further information, please contact:

DKSH Performance Materials
Daniel Hollister
Manager, Group Communications, Performance Materials
Phone +44 20 8879 5500
daniel.hollister@dksh.com

Novo Nordisk Pharmatech A/S
Vanessa León Toft
Marketing Manager
Phone +45 5667 1000
vnlt@novonordiskpharmatech.com
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>


White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>


Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement